Member Info for EmeraldCarrots

Please. "For the love of God, man, it is not a hearing test! ". Good example of posting complete rubbish. No one said it was a hearing test. Have you been drinking?

Go back to is it NICE with the data and if it is good enough the Genedrive MT-RNR1 test will be rolled out throughout the entire UK NHS. Surely, they must have tested 10,000 babies by now...... probably 10,000 to 15,000. How much data do they need?!!!

https://healthinnovationmanchester.com/news/health-innovation-manchester-celebrates-the-success-of-groundbreaking-genetic-test-preventing-newborn-hearing-loss/

"The Genedrive MT-RNR1 test, which identifies babies at risk of hearing loss after treatment with the antibiotic gentamicin, has already safeguarded the hearing of 11 newborns and tested over 4,000 babies as of October 2024.".

It's 17th July 2025 now. As I understand it they can go back to is it NICE with the data and if it is good enough the Genedrive MT-RNR1 test will be rolled out throughout the entire UK NHS. I wonder if that includes the likes of Bermuda etc. that are The British Overseas Territories. 14 territories that maintain a constitutional link with the United Kingdom, but are not part of the UK itself. Here is the list:-

Anguilla

Bermuda

British Antarctic Territory

British Indian Ocean Territory

British Virgin Islands

Cayman Islands

Falkland Islands

Gibraltar

Montserrat

Pitcairn, Henderson, Ducie and Oeno Islands

Saint Helena, Ascension and Tristan da Cunha

South Georgia and the South Sandwich Islands

Turks and Caicos Islands

Approval needed. There are ZERO holders of even 3%..... no major investors at all. Of course if I was offered say 8p a share I might be interested. I have over 1m shares.

1. One machine being evaluated at 14 NHS hospitals for use in neonatal wards.

2. Neonatal machine already to be rolled out to cover all of Scotland.

3. One machine for stroke wards has been evaluated and waiting for potential whole UK rollout.

4. Stroke machine also being evaluated for use in cardiovascular wards, again could be nationwide.

5. Market for neonatal ward machine in the USA absolutely enourmous, they need to get FDA approval first.

6. Ditto stroke ward machine.

All IMHO.

1. One machine being evaluated at 14 NHS hospitals for use in neonatal wards.

2. Neonatal machine to be rolled out to cover all of Scotland.

2. One machine for stroke wards has been evaluated and waiting for potential whole UK rollout.

3. Stroke machine also being evaluated for use in cardiovascular wards, again could be nationwide.

4. Market for neonatal ward machine in the USA absolutely enourmous, they need to get FDA approval first.

5. Ditto stroke ward machine.

To the currect sp. All that work inventing the 2 machines, then the years it has taken to get the NHS to actually use them. The amount of red tape in simply horrifying. NICE are enough to put any Company on Earth off trying to break into the NHS market. Yet 3p a share is now a 100% premium. It would be difficult for the Directors to mount a defence. Double the current market capitalisation is an excellent selling point for any bidder.

All IMHO.

TwoGood2Die.

The situation is totally and utterly ridiculous. Even without the new "dual analysis" Angle have possibly the best machine in the entire World for catching live, intact circulating tumour cells (CTC's) that are uncontaminated. This makes them perfect for analysis, especially DNA analysis.

Dual analysis moves this valuation to a whole different level. Dual analysis about doubles the chances of finding a cancer biomarker that can then be targeted by modern drugs. So about double the chance of being eligible for modern targeted treatment. Illumina AND Roche recognise this and have been talking to Angle. It all seems great until it comes to light that Angle have not managed to do a deal with either of them, or anyone else. There is a "deal making" issue here of biblical proportions. We need Donald Trump or someone else who is a deal maker. Angle's salespeople including the CEO Andrew Newland clearly do not have what it takes. He should step aside. The whole sales team need shaking up. I'm not selling. With the right management Angle will be a winner.

All IMHO.

Https://healthinnovationmanchester.com/news/health-innovation-manchester-celebrates-the-success-of-groundbreaking-genetic-test-preventing-newborn-hearing-loss/

"has been successfully implemented across all eight neonatal sites in Greater Manchester and will now be extended as part of a two-year study to 14 neonatal units across England, Scotland, Wales and Northern Ireland.".

Erm........... Scotland has already decided to implement the MT-RNR1, so why is one, or is it more than one included in the study? Maybe one in Scotland is being used to evaluate for the England/Wales/NI rollout?

MT-RNR1? Same goes for the Countries in the EU. This is a couple of announcements away from a rocketing share price IMHO. 3p plus easy.

Scotland have already decided thay want it.

The sales teams inablity to land big contracts is bordering on unbelievable. How on Earth can you deal with Astrazeneca, Illumina, Eisai inc. etc.. and NOT land big contracts? You would have thought if the sales side did NOTHING one or two big contracts would turn up.

All IMHO.

Of general blood (CtDna) and CTC's (circulating tumour cells) from the same tube of blood can't miss. CTC's that exhibit biomarkers are physically there in the blood and so need to be killed with a cancer drug. They help spread the cancer. They need to be eliminated. Advances in CtDna analysis will only help find more biomarkers in the blood and CTC's enabling more people to get targeted treatment. The market seems to not understand this. Illumina have already developed a dual analysis assay panel with Angle's help. The market ignores this too, for the moment.

All IMHO.

Step aside and let someone else run The Company. The whole sales side needs a shake up too. This Company has possibly the best CTC capture machine in the whole World. What a waste.

Genedrive's turnover is steadily increasing. The current market cap (shares in issue x share price) is £9 million. Gendrive's market is massive. We are only scratching the surface of the uk market now. We have the whole EU to follow and then the USA and indeed the whole World. Food for thought.

All IMHO.

So that would increase turnover per year to about £1.8 million excluding the initial cost of each machine. Just for the MT-RNR1, and just the UK ones.

We are heading for an obvious trading update that can only be extremely positive. Turnover will be projected to be multiples of last year IMHO. 2 to 4 times at least. Would not be surprised if yearly revenue projected to be 2 to £4 million.

All IMHO.

And that is heading for 14 hospitals as we know. The amount of consumables being used is ramping up.

4 tests per day x 7 days x 8 sites x 4 weeks = 896 per month? Then:

4 tests per day x 7 days x 14 sites x 4 weeks = 1,568 per month?

Soon adds up.

1,569 x £100 = £156,000 per month.

"It is now in use at eight Greater Manchester neonatal units and has has prevented the hearing loss of 11 babies across the region, with 4,000 babies tested as of October 2024.". 4000 tested as of October 2024. Must be more than 10,000 by now, some 8 months later?

Https://www.itv.com/news/granada/2024-11-21/new-test-to-prevent-newborn-babies-going-deaf-to-be-trialled-across-the-uk

Https://www.itv.com/news/granada/2024-11-21/new-test-to-prevent-newborn-babies-going-deaf-to-be-trialled-across-the-uk

Analysis including HER2 etc... The uses for the Parsortix machine are numerous. Anything you want to look at as far as circulating tumour cells (CTC's) go then Parsortix is the machine to have. The sales team at Angle are in my opinion not up to the job. Either that or the machine is massively overpriced. I can find no other explanation for the poor sales figures and lack of use of the machine in cancer drug trials. The sales team need a massive shake up, that is for sure. Also, the prices need to be adjusted downward. This situation is quite ridiculous. Apart from anything else it is slowing up cancer research. Dual analysis and "cluster buster" drug trials for starters.

All IMHO.

Interested to know.